#123 mTOR, Rapamycin and Beyond- Origins, Pharmacology, and Clinical Insights

1.5 CE Total | 1.5 Pharm

Now with AMA PRA Cat-1 CME (ACCME) Credit!

This course will have AMA PRA Cat-1 CME (ACCME) credit for one (1) year after being recorded on January 21, 2025. Renewal will be done through AANP.

Abstract:

While Rapamycin was discovered in 1975, it was not until the 1990’s that mTOR cell biology was elucidated. Since then, the once antifungal, antibiotic, and immune inhibiting drug has been proposed to have anti-cancer, anti-aging, and other properties. In this CE Dr. Anderson will review the discovery and pharmacology of Rapamycin, the biology and biochemistry of mTOR, and how the mTOR pathways can potentially be manipulated by the drug as well as natural substances (and other drugs).

Learning Objectives:

• Define the history of mTOR and Rapamycin
• Describe the data driven potential uses
• Describe “non-rapamycin” mTOR effectors
• Describe proper administration
• Define possible adverse events